Companies Cryptocurrencies
Allogene Therapeutics Inc
Allogene Therapeutics Inc
Exchange: NasdaqGS
IPO Date: 11/10/2018
CEO: Dr. David Chang
Biotechnology Healthcare đź”—
  • ALLO
  • 16.48
  • 2343175936
    market cap
  • -0.69000053
If you bought

shares of Allogene Therapeutics Inc (ALLO) on
You would have made
Old Price $12 Current Price $12

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 190 full-time employees. The firm is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Address: 210 E Grand Ave South San Francisco CALIFORNIA 94080

Stay updated.